TAO Synergies Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026or ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________Commission File Number:001-40458 TAO SYNERGIESINC.(Exact name of registrant as specified in its charter) (973) 242-0005(Registrant’s telephone number, including area code) Synaptogenix, Inc. (Former name, former address and former fiscalyear, if changed since last report) Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the SecuritiesExchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file suchreports), and (2)has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12months (or for such shorter period thatthe registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act) Yes☐No☒ As of May 13, 2026, there were 7,471,931 shares of the registrant’s common stock, $0.0001 par value per share, issuedand outstanding. CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION Certain statements in this report contain or may contain forward-looking statements. These statements,identified by words such as “plan,” “anticipate,” “believe,” “estimate,” “should,” “expect” and similar expressions,include our expectations and objectives regarding our future financial position, operating results and businessstrategy. These statements are subject to known and unknown risks, uncertainties and other factors which may causeactual results, performance or achievements to be materially different from any future results, performance orachievements expressed or implied by such forward-looking statements. These forward-looking statements were basedon various factors and were derived utilizing numerous assumptions and other factors that could cause our actualresults to differ materially from those in the forward-looking statements. These factors include, but are not limited to,our inability to obtain adequate financing, fluctuations in the price of our digital assets, potential decreases in thevalue of our digital assets and rewards, the significant length of time associated with drug development and relatedinsufficient cash flows and resulting illiquidity, our inability to expand our business, significant government regulationof pharmaceuticals and the healthcare industry, lack of product diversification, volatility in the price of our rawmaterials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, andour failure to implement our business plans or strategies. Most of these factors are difficult to predict accurately andare generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. You are cautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date of this report. You should carefully review this report in its entirety,including but not limited to our financial statements and the notes thereto and the risks described in Annual Report onForm 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the“SEC”) on March 31, 2026, as updated in our quarterly reports and current reports filed with the SEC from time totime. We advise you to carefully review the reports and documents we file from time to time with the SEC including ourcurrent reports on Form 8-K. Except for our ongoing obligations to disclose material information under securitieslaws, we undertake no obligation to publicly release any revisions to any forward-looking statements, to report eventsor to report the occurrence